Skip to main content

Articles

Page 25 of 38

  1. Adoptive immunotherapy is gaining momentum to fight malignancies, whereby γδ T cells have received recent attention as an alternative cell source as to natural killer cells and αβ T cells. The advent of γδ T c...

    Authors: Heleen H. Van Acker, Sébastien Anguille, Yannick Willemen, Johan M. Van den Bergh, Zwi N. Berneman, Eva Lion, Evelien L. Smits and Viggo F. Van Tendeloo
    Citation: Journal of Hematology & Oncology 2016 9:101
    Content type: Research Published on:

  2. Glycosylation is the most complex post-translational modification of proteins. Altered glycans on the tumor- and host-cell surface and in the tumor microenvironment have been identified to mediate critical eve...

    Authors: Wan-Ling Ho, Wen-Ming Hsu, Min-Chuan Huang, Kenji Kadomatsu and Akira Nakagawara
    Citation: Journal of Hematology & Oncology 2016 9:100
    Content type: Review Published on:

  3. Neuroblastoma is a relatively common and highly belligerent childhood tumor with poor prognosis by current therapeutic approaches. A novel anti-cancer agent of the di-2-pyridylketone thiosemicarbazone series, ...

    Authors: Zhu-Ling Guo, Des R. Richardson, Danuta S. Kalinowski, Zaklina Kovacevic, Kian Cheng Tan-Un and Godfrey Chi-Fung Chan
    Citation: Journal of Hematology & Oncology 2016 9:98
    Content type: Research Published on:

  4. Antifungal prophylaxis is currently regarded as the gold standard in situations with allo-genetic hematopoietic stem cell transplantation (allo-HSCT). However, the epidemiological information regarding prophyl...

    Authors: Lei Gao, Yuqian Sun, Fanyi Meng, Mingzhe Han, He Huang, Depei Wu, Li Yu, Hanyun Ren, Xiaojun Huang and Xi Zhang
    Citation: Journal of Hematology & Oncology 2016 9:97
    Content type: Research Published on:

  5. Pembrolizumab is a monoclonal antibody that is designed against programmed cell death protein 1 (PD-1). Pembrolizumab and other immunocheckpoint-blocking monoclonal antibodies work by modulating a patient’s ow...

    Authors: Gregory S. Alexander, Joshua D. Palmer, Madalina Tuluc, Jianqing Lin, Adam P. Dicker, Voichita Bar-Ad, Larry A Harshyne, Jennifer Louie, Colette M. Shaw, D. Craig Hooper and Bo Lu
    Citation: Journal of Hematology & Oncology 2016 9:96
    Content type: Case report Published on:

  6. GATA3 is pivotal for the development of T lymphocytes. While its effects in later stages of T cell differentiation are well recognized, the role of GATA3 in the generation of early T c...

    Authors: L. Fransecky, M. Neumann, S. Heesch, C. Schlee, J. Ortiz-Tanchez, S. Heller, M. Mossner, S. Schwartz, L. H. Mochmann, K. Isaakidis, L. Bastian, U. R. Kees, T. Herold, K. Spiekermann, N. Gökbuget and C. D. Baldus
    Citation: Journal of Hematology & Oncology 2016 9:95
    Content type: Research Published on:

  7. The existence and identification of leukemia-initiating cells in adult acute B lymphoblastic leukemia (B-ALL) remain controversial. We examined whether adult B-ALL is hierarchically organized into phenotypical...

    Authors: Zhiwu Jiang, Manman Deng, Xinru Wei, Wei Ye, Yiren Xiao, Simiao Lin, Suna Wang, Baiheng Li, Xin Liu, Gong Zhang, Peilong Lai, Jianyu Weng, Donghai Wu, Haijia Chen, Wei Wei, Yuguo Ma…
    Citation: Journal of Hematology & Oncology 2016 9:94
    Content type: Letter to the Editor Published on:

  8. The poor outcomes for patients diagnosed with acute myeloid leukemia (AML) are largely attributed to leukemia stem cells (LSCs) which are difficult to eliminate with conventional therapy and responsible for re...

    Authors: Yahui Ding, Huier Gao, Yu Zhang, Ye Li, Neil Vasdev, Yingdai Gao, Yue Chen and Quan Zhang
    Citation: Journal of Hematology & Oncology 2016 9:93
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:61

  9. Patient derived xenografts (PDX) are generated by transplanting the original patient’s tumor tissue into immune-deficient mice. Unlike xenograft models derived from cell lines, PDX models can better preserve t...

    Authors: Ruifen Dong, Wenan Qiang, Haiyang Guo, Xiaofei Xu, J. Julie Kim, Andrew Mazar, Beihua Kong and Jian-Jun Wei
    Citation: Journal of Hematology & Oncology 2016 9:92
    Content type: Research Published on:

  10. NT1014 is a novel biguanide and AMPK activator with a high affinity for the organic cation-specific transporters, OCT1 and OCT3. We sought to determine the anti-tumorigenic effects of NT1014 in human ovarian c...

    Authors: Lu Zhang, Jianjun Han, Amanda L. Jackson, Leslie N. Clark, Joshua Kilgore, Hui Guo, Nick Livingston, Kenneth Batchelor, Yajie Yin, Timothy P. Gilliam, Paola A. Gehrig, Xiugui Sheng, Chunxiao Zhou and Victoria L. Bae-Jump
    Citation: Journal of Hematology & Oncology 2016 9:91
    Content type: Research Published on:

  11. B cell-specific Moloney murine leukemia virus integration site 1 (Bmi-1) plays an important role in regulating stemness in some kinds of cancer. However, the mechanisms remain unclear. This study was to invest...

    Authors: Xiaofeng Wang, Chang Wang, Xiaowei Zhang, Ruixi Hua, Lu Gan, Mingzhu Huang, Liqin Zhao, Sujie Ni and Weijian Guo
    Citation: Journal of Hematology & Oncology 2016 9:90
    Content type: Research Published on:

  12. Allogeneic stem cell transplantation is the only curative option for patients with acute myeloid leukemia (AML) experiencing relapse. Either matched sibling donor (MSD) or unrelated donor (UD) is indicated.

    Authors: Annalisa Ruggeri, Giorgia Battipaglia, Myriam Labopin, Gerhard Ehninger, Dietrich Beelen, Johanna Tischer, Arnold Ganser, Rainer Schwerdtfeger, Bertram Glass, Jurgen Finke, Mauricette Michallet, Matthias Stelljes, Pavel Jindra, Renate Arnold, Nicolaus Kröger, Mohamad Mohty…
    Citation: Journal of Hematology & Oncology 2016 9:89
    Content type: Research Published on:

  13. In chronic lymphocytic leukemia (CLL), next-generation sequencing (NGS) analysis represents a sensitive, reproducible, and resource-efficient technique for routine screening of gene mutations.

    Authors: Gian Matteo Rigolin, Elena Saccenti, Cristian Bassi, Laura Lupini, Francesca Maria Quaglia, Maurizio Cavallari, Sara Martinelli, Luca Formigaro, Enrico Lista, Maria Antonella Bardi, Eleonora Volta, Elisa Tammiso, Aurora Melandri, Antonio Urso, Francesco Cavazzini, Massimo Negrini…
    Citation: Journal of Hematology & Oncology 2016 9:88
    Content type: Research Published on:

    The Erratum to this article has been published in Journal of Hematology & Oncology 2016 9:103

  14. Persons with acute leukemia relapsing after allotransplant and who respond to anti-leukemia interventions are at high risk of a second relapse. We studied the impact of minimal residual disease (MRD)- and graf...

    Authors: Chen-Hua Yan, Yu Wang, Jing-Zhi Wang, Yu-Hong Chen, Yao Chen, Feng-rong Wang, Yu-Qian Sun, Xiao-Dong Mo, Wei Han, Huan Chen, Xiao-hui Zhang, Lan-Ping Xu, Kai-Yan Liu and Xiao-Jun Huang
    Citation: Journal of Hematology & Oncology 2016 9:87
    Content type: Rapid communication Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:24

  15. Detecting epidermal growth factor receptor (EGFR) activating mutations in plasma could guide EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment for advanced non-small cell lung cancer (NSCLC). However, dynamic q...

    Authors: Qing Zhou, Jin-Ji Yang, Zhi-Hong Chen, Xu-Chao Zhang, Hong-Hong Yan, Chong-Rui Xu, Jian Su, Hua-Jun Chen, Hai-Yan Tu, Wen-Zhao Zhong, Xue-Ning Yang and Yi-Long Wu
    Citation: Journal of Hematology & Oncology 2016 9:86
    Content type: Research Published on:

  16. The advent of next-generation sequencing technologies has unveiled a new window into the heterogeneity of acute myeloid leukemia (AML). In particular, recurrent mutations in spliceosome machinery and genome-wi...

    Authors: Rosalia de Necochea-Campion, Geoffrey P. Shouse, Qi Zhou, Saied Mirshahidi and Chien-Shing Chen
    Citation: Journal of Hematology & Oncology 2016 9:85
    Content type: Review Published on:

  17. Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is the most frequent subtype of secondary HLH triggered by infections. Previous studies have shown that ~30 % or more of patients with...

    Authors: Jingshi Wang, Yini Wang, Lin Wu, Jia Zhang, Wenyuan Lai and Zhao Wang
    Citation: Journal of Hematology & Oncology 2016 9:84
    Content type: Research Published on:

  18. The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-assoc...

    Authors: Yijun Tian, Kongming Wu, Qian Liu, Na Han, Li Zhang, Qian Chu and Yuan Chen
    Citation: Journal of Hematology & Oncology 2016 9:83
    Content type: Research Published on:

  19. Drug combinations of the proteasome inhibitor bortezomib with cytotoxic chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric acute myeloid leukaemia (AML) and acute lymp...

    Authors: Denise Niewerth, Gertjan J. L. Kaspers, Gerrit Jansen, Johan van Meerloo, Sonja Zweegman, Gaye Jenkins, James A. Whitlock, Stephen P. Hunger, Xiaomin Lu, Todd A. Alonzo, Peter M. van de Ven, Terzah M. Horton and Jacqueline Cloos
    Citation: Journal of Hematology & Oncology 2016 9:82
    Content type: Research Published on:

  20. Novel immunotherapies, or checkpoint inhibitors, targeting programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have significantly improved outcomes for patients with...

    Authors: Marc Uemura, Van A. Trinh, Cara Haymaker, Natalie Jackson, Dae Won Kim, James P. Allison, Padmanee Sharma, Luis Vence, Chantale Bernatchez, Patrick Hwu and Adi Diab
    Citation: Journal of Hematology & Oncology 2016 9:81
    Content type: Case report Published on:

  21. Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects...

    Authors: Jingjing Wu, Christina Liu, Stella T. Tsui and Delong Liu
    Citation: Journal of Hematology & Oncology 2016 9:80
    Content type: Review Published on:

  22. Optimal post-remission strategy for patients with acute myeloid leukemia (AML) is matter of intense debate. Recent reports have shown stronger anti-leukemic activity but similar survival for allogeneic stem ce...

    Authors: Francesco Saraceni, Myriam Labopin, Norbert-Claude Gorin, Didier Blaise, Reza Tabrizi, Liisa Volin, Jan Cornelissen, Jean-Yves Cahn, Patrice Chevallier, Charles Craddock, Depei Wu, Anne Huynh, William Arcese, Mohamad Mohty and Arnon Nagler
    Citation: Journal of Hematology & Oncology 2016 9:79
    Content type: Research Published on:

  23. Risk stratification based on cytogenetics of acute myeloid leukemia (AML) remains imprecise. The introduction of novel genetic and epigenetic markers has helped to close this gap and increased the specificity ...

    Authors: Stefan Wilop, Wen-Chien Chou, Edgar Jost, Martina Crysandt, Jens Panse, Ming-Kai Chuang, Tim H. Brümmendorf, Wolfgang Wagner, Hwei-Fang Tien and Behzad Kharabi Masouleh
    Citation: Journal of Hematology & Oncology 2016 9:78
    Content type: Research Published on:

  24. Glioblastoma multiforme (GBM), a common primary malignant brain tumor, rarely disseminates beyond the central nervous system and has a very bad prognosis. The current study aimed at the analysis of immunologic...

    Authors: Haouraa Mostafa, Andrej Pala, Josef Högel, Michal Hlavac, Elvira Dietrich, M. Andrew Westhoff, Lisa Nonnenmacher, Timo Burster, Michael Georgieff, C. Rainer Wirtz and E. Marion Schneider
    Citation: Journal of Hematology & Oncology 2016 9:77
    Content type: Research Published on:

  25. Trastuzumab, a humanized antibody targeting HER2, exhibits remarkable therapeutic efficacy against HER2-positive gastric cancer. However, recurrent therapeutic resistance presents revolutionary claims. Warburg...

    Authors: Jing Liu, Changqie Pan, Lihong Guo, Mengwan Wu, Jing Guo, Sheng Peng, Qianying Wu and Qiang Zuo
    Citation: Journal of Hematology & Oncology 2016 9:76
    Content type: Research Published on:

  26. Multiple myeloma is an incurable complex disease characterized by clonal proliferation of malignant plasma cells in a hypoxic bone marrow environment. Hypoxia-dependent erythropoietin (EPO)-receptor (EPOR) sig...

    Authors: Thea Kristin Våtsveen, Anne-Marit Sponaas, Erming Tian, Qing Zhang, Kristine Misund, Anders Sundan, Magne Børset, Anders Waage and Gaute Brede
    Citation: Journal of Hematology & Oncology 2016 9:75
    Content type: Research Published on:

  27. Hepatocellular carcinoma (HCC) remains one of the most common and lethal malignancies worldwide despite the development of various therapeutic strategies. A better understanding of the mechanisms responsible f...

    Authors: Aparna Jayachandran, Bijay Dhungel and Jason C. Steel
    Citation: Journal of Hematology & Oncology 2016 9:74
    Content type: Review Published on:

  28. Acquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent advanced treatment options such as liposomal formulations, proteasome inhibitors, immunomo...

    Authors: Joel G. Turner, Jana L. Dawson, Steven Grant, Kenneth H. Shain, William S. Dalton, Yun Dai, Mark Meads, Rachid Baz, Michael Kauffman, Sharon Shacham and Daniel M. Sullivan
    Citation: Journal of Hematology & Oncology 2016 9:73
    Content type: Research Published on:

  29. We demonstrate the synergistic antitumor effect of oridonin and the PI3K/mTOR inhibitor NVP-BEZ235 on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma (non-GCB DLBCL) both in vitro ...

    Authors: Kai Qing, Zhen Jin, Wanbin Fu, Wenfang Wang, Zhao Liu, Xiaoyang Li, Zizhen Xu and Junmin Li
    Citation: Journal of Hematology & Oncology 2016 9:72
    Content type: Letter to the Editor Published on:

  30. The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoi...

    Authors: Michael M. B. Green, Nelson Chao, Saurabh Chhabra, Kelly Corbet, Cristina Gasparetto, Ari Horwitz, Zhiguo Li, Jagadish Kummetha Venkata, Gwynn Long, Alice Mims, David Rizzieri, Stefanie Sarantopoulos, Robert Stuart, Anthony D. Sung, Keith M. Sullivan, Luciano Costa…
    Citation: Journal of Hematology & Oncology 2016 9:71
    Content type: Research Published on:

  31. Chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19) have shown therapeutical activities in CD19+ malignancies. However, the etiological nature of neurologic complications remains a conundr...

    Authors: Yongxian Hu, Jie Sun, Zhao Wu, Jian Yu, Qu Cui, Chengfei Pu, Bin Liang, Yi Luo, Jimin Shi, Aiyun Jin, Lei Xiao and He Huang
    Citation: Journal of Hematology & Oncology 2016 9:70
    Content type: Letter to the Editor Published on:

  32. Abnormal expression of SOCS3 has been implicated in myeloproliferative neoplasms, but the role of SOCS3 in the pathogenesis of leukemia remains largely unknown. Here, we examined the function of SOCS3 in the g...

    Authors: Yu-xiao Liu, Li Wang, Wen-jia Liu, Hai-tao Zhang, Jing-hui Xue, Zhi-wen Zhang and Chun-ji Gao
    Citation: Journal of Hematology & Oncology 2016 9:69
    Content type: Research Published on:

  33. The treatment of metastatic breast cancer (MBC) remains a great clinical challenge as drug resistance frequently develops. Alternative agents that can overcome drug resistance would offer new therapeutic optio...

    Authors: Pin Zhang, Zhongsheng Tong, Fuguo Tian, Yongsheng Wang, Junlan Yang, Weilian Li, Lijun Di, Wei Liu, Li Tang, Rongguo Qiu and Binghe Xu
    Citation: Journal of Hematology & Oncology 2016 9:68
    Content type: Research Published on:

  34. Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative in a variety of hematological malignancies. Graft-vs.-host disease (GvHD) remains a life-threatening complication. Standard tre...

    Authors: Enrico Maffini, Luisa Giaccone, Moreno Festuccia, Lucia Brunello, Ilaria Buondonno, Dario Ferrero, Mario Boccadoro, Chiara Dellacasa, Alessandro Busca, Domenico Novero and Benedetto Bruno
    Citation: Journal of Hematology & Oncology 2016 9:67
    Content type: Case report Published on:

  35. Crizotinib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity against mesenchymal-epithelial transition factor (MET) and anaplastic lymphoma kinase (ALK). However, the concomitant oncogenic driv...

    Authors: Fei-fei Gu, Yong Zhang, Yang-yang Liu, Xiao-hua Hong, Jin-yan Liang, Fan Tong, Jing-song Yang and Li Liu
    Citation: Journal of Hematology & Oncology 2016 9:66
    Content type: Letter to the Editor Published on:

  36. Data comparing fully matched and mismatched-unrelated-donor (M- and mM-URD) allogeneic hematopoietic stem cell transplant (allo-SCT) following reduced intensity conditioning regimens for acute myeloid leukemia...

    Authors: Marie T. Rubio, Bipin N. Savani, Myriam Labopin, Emmanuelle Polge, Dietger Niederwieser, Arnold Ganser, Rainer Schwerdtfeger, Gerhard Ehninger, Jürgen Finke, Arnold Renate, Charles Craddock, Nicolaus Kröger, Michael Hallek, Pavel Jindra, Mohamad Mohty and Arnon Nagler
    Citation: Journal of Hematology & Oncology 2016 9:65
    Content type: Research Published on:

  37. The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for ...

    Authors: Hasan Mahmud, Steven M. Kornblau, Arja ter Elst, Frank J. G. Scherpen, Yi Hua Qiu, Kevin R. Coombes and Eveline S. J. M. de Bont
    Citation: Journal of Hematology & Oncology 2016 9:64
    Content type: Letter to the Editor Published on:

  38. We studied telomere length in 32 CML patients who discontinued imatinib after achieving complete molecular remission and 32 age-sex-matched controls. The relative telomere length (RTL) was determined by q-PCR ...

    Authors: Giovanni Caocci, Marianna Greco, Giuseppe Delogu, Christian Secchi, Bruno Martino, Claudia Labate, Elisabetta Abruzzese, Malgorzata Monika Trawinska, Sara Galimberti, Federica Orru, Claudio Fozza, Carlo Gambacorti Passerini, Francesco Galimi and Giorgio La Nasa
    Citation: Journal of Hematology & Oncology 2016 9:63
    Content type: Letter to the Editor Published on:

  39. Telomere erosion can lead to genomic instability and cancer progression. It has been suggested that the shortest telomere, not the average telomere length (TL), is critical for cell viability. Some studies hav...

    Authors: Sang Mee Hwang, Seon Young Kim, Jung Ah Kim, Hee-Sue Park, Si Nae Park, Kyongok Im, Kwantae Kim, Sung-Min Kim and Dong Soon Lee
    Citation: Journal of Hematology & Oncology 2016 9:62
    Content type: Research Published on:

  41. Venous thromboembolism (VTE) is a well-recognised and life-threatening complication in patients with cancer. However, the precise risk of VTE in hospitalised cancer patients in England has not been previously ...

    Authors: Sonia Ratib, Alex J. Walker, Tim R. Card and Matthew J. Grainge
    Citation: Journal of Hematology & Oncology 2016 9:60
    Content type: Research Published on:

  42. T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR). Several third-generation EGFR mutant select...

    Authors: Shuhang Wang, Stella T. Tsui, Christina Liu, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2016 9:59
    Content type: Review Published on:

  44. Recent evidence indicates that long noncoding RNAs (lncRNAs) play pivotal roles in the regulation of cellular processes and are found to be dysregulated in a variety of cancers. LINC00261 is an lncRNA that is ...

    Authors: Yu Fan, Yan-fen Wang, Hua-fang Su, Na Fang, Chen Zou, Wen-feng Li and Zheng-hua Fei
    Citation: Journal of Hematology & Oncology 2016 9:57
    Content type: Research Published on:

    The Retraction Note to this article has been published in Journal of Hematology & Oncology 2018 11:2

  45. The poor prognosis and the limited efficacy of targeted therapy in patients with triple-negative breast cancer (TNBC) have raised the need for alternative therapies. Recent studies have demonstrated that folat...

    Authors: De-Gang Song, Qunrui Ye, Mathilde Poussin, Jessica A. Chacon, Mariangela Figini and Daniel J. Powell Jr.
    Citation: Journal of Hematology & Oncology 2016 9:56
    Content type: Research Published on:

  46. Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well ...

    Authors: Yucai Wang, Larysa Sanchez, David S. Siegel and Michael L. Wang
    Citation: Journal of Hematology & Oncology 2016 9:55
    Content type: Review Published on:

  47. The purpose of this study was to better understand the efficacy and safety of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma(R/RMM).

    Authors: Liping Liu, Ningning Zhao, Wenjun Xu, Zhixin Sheng and Lida Wang
    Citation: Journal of Hematology & Oncology 2016 9:54
    Content type: Letter to the Editor Published on:

  48. Previous studies have demonstrated that regulatory T cells (Tregs) play a protective role in the pathogenesis of chronic graft-versus-host disease (cGVHD). Tregs constitutively express the gene of the transcri...

    Authors: Gilles Fransolet, Grégory Ehx, Joan Somja, Loïc Delens, Muriel Hannon, Joséphine Muller, Sophie Dubois, Pierre Drion, Jo Caers, Stéphanie Humblet-Baron, Philippe Delvenne, Yves Beguin, Giuseppina Conteduca and Frédéric Baron
    Citation: Journal of Hematology & Oncology 2016 9:53
    Content type: Research Published on:

  50. Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death ...

    Authors: Larysa Sanchez, Yucai Wang, David S. Siegel and Michael L. Wang
    Citation: Journal of Hematology & Oncology 2016 9:51
    Content type: Review Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us